Company: SRPT
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058003
Chunk: 99

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 99
---
’s employees to leave their employment with the Company during, and for eighteen months following, the term of his employment. In addition, Mr. Ingram entered into the Company’s form of Confidential Proprietary Rights and Non-Disclosure Agreement.

Also on June 26, 2017, we entered into a Change in Control Agreement with Mr. Ingram (“CIC Severance Agreement”). The CIC Severance Agreement provides that if Mr. Ingram experiences a termination by the Company without cause or by him for good reason during the 90-day period preceding or the 24-month period following a change in control, then in addition to his Accrued Benefits, we will provide Mr. Ingram with the following payments and benefits, subject to his execution and non-revocation of a release of claims:

a cash lump sum payment equal to 24 months of his base salary at the rate in effect immediately prior to his termination of employment;

a cash lump sum payment equal to 200% of his annual target bonus assuming achievement of performance goals at 100%;

accelerated vesting on 100% of his outstanding and unvested equity awards other than his Performance Option Award; and

COBRA coverage at applicable active employee rates for 18 months following termination.

The 2022 Letter Agreement amended the CIC Severance Agreement with respect to the treatment of the Performance Option in the event of a change in control to provide that in the event of a Covered Termination

<div align='center'>72</div>

during a Change in Control Period (each as defined in the CIC Agreement), any unvested portion of the Performance Option will become vested with respect to that number of shares subject to the option that would have vested upon achievement of any of the stock price targets associated with such award (the “Stock Price Targets”) if the Company’s compounded annual growth rate (“CAGR”) in the closing price of the Company’s common stock from April 19, 2022 (the “Amendment Effective Date”) to the date of the change in control (“Company CIC CAGR”) equals or exceeds the CAGR of the closing price of the Company’s common stock during the three-year period specified in the 2022 Letter Agreement that would have been required to achieve the corresponding Stock Price Targets on June 26, 2025, subject to certain conditions (the “CIC Performance Option Termination Treatment”). However, under the CIC Performance Option Termination Treatment, no such vesting will occur if the sale price of the Company